Additionally, PPARγ’s therapeutic benefit has significant overlap with several of the previously discussed targets in this section, including BMPR2 and TGF-β signaling [105,114,115] and the RAS system as Ang II inhibition increased PPARγ expression in murine models of renal fibrosis [116]. The gene discussed is PPARG; the disease is renal fibrosis.